Sage Journals: Discover world-class research

Abstract

Background:

Autologous platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMC) are being used clinically as therapeutic agents for the treatment of knee osteoarthritis.

Purpose/Hypothesis:

The purpose of this study was to compare the efficacy of BMC and PRP on pain and function in patients with knee osteoarthritis up to 24 months after injection. It was hypothesized that patients receiving BMC would have better sustained outcomes than those receiving PRP.

Study Design:

Randomized controlled trial; Level of evidence, 2.

Methods:

A total of 90 participants aged between 18 and 80 years with symptomatic knee osteoarthritis (Kellgren-Lawrence grades 1-3) were randomized into 2 study groups: PRP and BMC. Both groups completed the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and subjective International Knee Documentation Committee (IKDC) questionnaire before and 1, 3, 6, 9, 12, 18, and 24 months after a single intra-articular injection of leukocyte-rich PRP or BMC. A linear mixed-effects model was performed to quantify the effects over time and the difference between the groups. This model has the random effect for time to assess the extent in which the change over time differs from one person to another.

Results:

An overall 84 patients completed questionnaires from baseline to 12 months; however, 17 patients (n = 9; PRP group) were lost to follow-up at 18 months and 25 (n = 13; PRP group) at 24 months. There were no statistically significant differences in IKDC (P = .909; 95% CI, −6.26 to 7.03) or WOMAC (P = .789; 95% CI, −6.26 to 4.77) scores over time between the groups. Both groups had significantly improved IKDC (P < .001; 95% CI, 0.275-0.596) and WOMAC (P = .001; 95% CI, −0.41 to −0.13) scores from baseline to 24 months after the injection. These improvements plateaued at 3 months and were sustained for 24 months after the injection, with no difference between PRP and BMC at any time point.

Conclusions:

For the treatment of osteoarthritis, PRP and BMC performed similarly out to 24 months. BMC was not superior to PRP.

Registration:

NCT03289416 (ClincalTrials.gov identifier).

Keywords

bone marrow aspirate bone marrow aspirate concentrate osteoarthritis platelet-rich plasma regenerative medicine

Get full access to this article

View all access options for this article.

References

Abbott

Hobbs

Gwynne-Jones

. MOA Trial Team. The ShortMAC: minimum important change of a reduced version of the Western Ontario and McMaster Universities Osteoarthritis Index. J Orthop Sports Phys Ther. 2018;48(2):81-86.

Anz

Hubbard

Rendos

Everts

Andrews

Hackel

. Bone marrow aspirate concentrate is equivalent to platelet-rich plasma for the treatment of knee osteoarthritis at 1 year: a prospective, randomized trial. Orthop J Sports Med. 2020;8(2):2325967119900958.

Brown

Johnston

Saltzman

Marsh

Buckwalter

. Posttraumatic osteoarthritis: a first estimate of incidence, prevalence, and burden of disease. J Orthop Trauma. 2006;20(10):739-744.

Cassano

Kennedy

Ross

Fraser

Goodale

Fortier

. Bone marrow concentrate and platelet-rich plasma differ in cell distribution and interleukin 1 receptor antagonist protein concentration. Knee Surg Sports Traumatol Arthrosc. 2018;26(1):333-342.

Centeno

Pitts

Al-Sayegh

Freeman

. Efficacy of autologous bone marrow concentrate for knee osteoarthritis with and without adipose graft. Biomed Res Int. 2014;2014:370621.

Centeno

Al-Sayegh

Bashir

Goodyear

Freeman

. A dose response analysis of a specific bone marrow concentrate treatment protocol for knee osteoarthritis. BMC Musculoskelet Disord. 2015;16:258.

Chouhan

Dhillon

Patel

Bansai

Bhatia

Kanwat H . Multiple platelet-rich plasma injections versus single platelet-rich plasma injection in early osteoarthritis of the knee: an experimental study in guinea pig model of early knee osteoarthritis. Am J Sports Med. 2019;47(10):2300-2307.

Clement

Bardgett

Weir

Holland

Gerrand

Deehan

. What is the minimum clinically important difference for the WOMAC after TKA? Clin Orthop Relat Res. 2018;476(10):2005-2014.

Dai

Zhou

Zhang

. Efficacy of platelet-rich plasma in the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. Arthroscopy. 2017;33(3):659-670, e651.

10.

Di Matteo

Vandenbulcke

Vitale

, et al. Minimally manipulated mesenchymal stem cells for the treatment of knee osteoarthritis: a systematic review of clinical evidence. Stem Cells Int. 2019;2019:1735242.

11.

Felson

Lawrence

Dieppe

, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:637-639.

12.

Felson

Zhang

Hannan

, et al. The incidence and natural history of knee osteoarthritis in the eldery. Arthritis Rheum. 1995;38(10):1500-1505.

13.

Filardo

Di Matteo

Di Martino

, et al. Platelet-rich plasma intra-articular knee injections show no superiority versus viscosupplementation: a randomized controlled trial. Am J Sports Med. 2015;43(7):1575-1582.

14.

Finch

Bolin

Kelley

. Multilevel Modeling Using R. Vol 1. CRC Press; 2014.

15.

Gaul

Bugbee

Hoenecke

Jr D’Lima

. A review of commercially available point-of-care devices to concentrate bone marrow for the treatment of osteoarthritis and focal cartilage lesions. Cartilage. 2019;10(4):387-394.

16.

Goldring

. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192(1):230-237.

17.

Hedeker

Gibbons

. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods. 1997;2(1):64-78.

18.

Hernigou

Homma

Flouzat Lachaniette

, et al. Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. Int Orthop. 2013;37(11):2279-2287.

19.

Irrgang

Anderson

Boland

, et al. Responsiveness of the International Knee Documentation Committee subjective knee form. Am J Sports Med. 2006;34(10):1567-1573.

20.

Khatab

van Buul

Kops

, et al. Intra-articular injections of platelet-rich plasma releasate reduce pain and synovial inflammation in a mouse model of osteoarthritis. Am J Sports Med. 2018;46(4):977-986.

21.

Kon

Mandelbaum

Buda

, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy. 2011;27(11):1490-1501.

22.

Lieberthal

Sambamurthy

Scanzello

. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015;23:1825-1834.

23.

Mautner

Bowers

Easley

Fausel

Robinson

. Functional outcomes following microfragmented adipose tissue versus bone marrow aspirate concentrate injections for symptomatic knee osteoarthritis. Stem Cells Transl Med. 2019;8(11):1149-1156.

24.

Meheux

McCulloch

Lintner

Varner

Harris

. Efficacy of intra-articular platelet-rich plasma injections in knee osteoarthritis: a systematic review. Arthroscopy. 2016;32(3):495-505.

25.

Murphy

Schwartz

Helmick

, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207-1213.

26.

Muschler

Boehm

Easley

. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am. 1997;79(11):1699-1709.

27.

Oliver

Awan

Bayes

. Single- versus multiple-site harvesting techniques for bone marrow concentrate: evaluation of aspirate quality and pain. Orthop J Sports Med. 2017;5(8):2325967117724398.

28.

Piuzzi

Kantor

, et al. What is the price and claimed efficacy of platelet-rich plasma injections for the treatment of knee osteoarthritis in the United States? J Knee Surg. 2019;32(9):879-885.

29.

Riboh

Saltzman

Yanke

Fortier

Cole

. Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med. 2016;44(3):792-800.

30.

Rodriguez-Fontan

Piuzzi

Kraeutler

Pascual-Garrido

. Early clinical outcomes of intra-articular injections of bone marrow aspirate concentrate for the treatment of early osteoarthritis of the hip and knee: a cohort study. PM R. 2018;10(12):1353-1359.

31.

Rubin

Witkiewitz

St Andre

Reilly

. Methods for handling missing data in the behavioral neurosciences: don’t throw the baby rat out with the bath water. J Undergrad Neurosci. 2007;5(2):A71-A77.

32.

Sampson

Smith

Vincent

Aufiero

Zall

Botta-van-Bemden

. Intra-articular bone marrow concentrate injection protocol: short-term efficacy in osteoarthritis. Regen Med. 2016;11(6):511-520.

33.

Shapiro

Arthurs

Heckman

, et al. Quantitative T2 MRI mapping and 12-month follow-up in a randomized, blinded, placebo controlled trial of bone marrow aspiration and concentration for osteoarthritis of the knees. Cartilage. 2019;10(4):432-443.

34.

Shapiro

Kazmerchak

Heckman

Zubair

O’Connor

. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am J Sports Med. 2017;45(1):82-90.

35.

Shaw

Darrow

Derian

. Short-term outcomes in treatment of knee osteoarthritis with 4 bone marrow concentrate injections. Clin Med Insights Arthritis Musculoskelet Disord. 2018;11:1179544118781080.

36.

Spakova

Rosocha

Lacko

Harvanova

Gharaibeh

. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil. 2012;91(5):411-417.

37.

Themistocleous

Chloros

Kyrantzoulis

, et al. Effectiveness of a single intra-articular bone marrow aspirate concentrate (BMAC) injection in patients with grade 3 and 4 knee osteoarthritis. Heliyon. 2018;4(10):e00871.

38.

Wang

Shimmin

Ghosh

, et al. Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial. Arthritis Res Ther. 2017;19(1):180.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB

Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial